Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: A systematic review

Depression and Anxiety

Volumn 29, Issue 6, 2012, Pages 495-505

  Thaler, Kylie J ^a   Morgan, Laura C ^b   Van Noord, Megan ^c   Gaynes, Bradley N ^c   Hansen, Richard A ^d   Lux, Linda J ^b   Krebs, Erin E ^e   Lohr, Kathleen N ^b   Gartlehner, Gerald ^a,b  

^a DANUBE UNIVERSITY KREMS   (Austria)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d AUBURN UNIVERSITY   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

antidepressants; anxiety anxiety disorders; chronic pain; Clinical Trials; depression; treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ANXIETY; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CHRONIC PAIN; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84862766012     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.21951     Document Type: Review

References (50)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289 (23): 3095-3105. (Pubitemid 37432885)
2. American Psychiatric Association, Practice guideline for the treatment of patients with major depressive disorder, third edition, Work Group on Major Depressive Disorder Independent Review Panel, Editor 2010, Psychiatry Online: Arlington, VA.
3. Drug Information Online. Drugs.Com. 2011. Available at:. Retrieved November 25, 2011.
4. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis. Annals of internal medicine 2011; 155 (11): 772-785.
5. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 2009; 373 (9665): 746-758.
6. Turner E, Moreno SG, Sutton AJ,. Ranking antidepressants. Lancet 2009; 373 (9677): 1760; author reply 1761-1762.
7. Gartlehner G, Gaynes BN, Hansen RA, Lohr KN,. Ranking antidepressants. Lancet 2009; 373 (9677): 1761; author reply 1761-1762.
8. Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists' selection of antidepressants? The American journal of psychiatry 2004; 161 (7): 1285-1289. (Pubitemid 38859180)
9. Gartlenhner G, Hansen RA, Morgan LC, et al. Comparative effectiveness of second generation antidepressants in the pharmacologic treatment of adult depression: An update to a 2007 report, Agency for Healthcare Research and Quality, 2011, (Prepared by the RTI International-University of North Carolina Evidence-based Practice Center, Contract No. 29200710056I#2) Agency for Healthcare Research and Quality: Rockville, MD.
10. Quality AfHRa. What is comparative effectiveness research? 2011. Available at:. Retrieved November 26, 2011.
11. Gaynes BN, Rush AJ, Trivedi M, et al. A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the star*d clinical trial. Gen Hosp Psychiatry 2005; 27 (2): 87-96. (Pubitemid 40348772)
12. Gaynes BN, Rush AJ, Trivedi MH, et al. Major depression symptoms in primary care and psychiatric care settings: A cross-sectional analysis. Ann Fam Med 2007; 5 (2): 126-134. (Pubitemid 46513481)
13. Chapman AL, Morgan LC, Gartlehner G,. Semi-automating the manual literature search for systematic reviews increases efficiency. Health Info Libr J 2010; 27 (1): 22-27.
14. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US preventive services task force: A review of the process. Am J Prev Med, 2001. 20 (3 Suppl): p. 21-35. (Pubitemid 33732964)
15. The Nordic Cochrane Centre. Review manager (revman), T.C. Collaboration, editor. Copenhagen. 2011.
16. Balshem H, Helfand M, Schunemann HJ, et al. Grade guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64 (4): 401-406.
17. Mao PX, Tang YL, Jiang F, et al. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a chinese population. Depress anxiety 2008; 25 (1): 46-54. (Pubitemid 351213924)
18. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 (Suppl 2): 46-52. (Pubitemid 26146709)
19. Chouinard G, Saxena B, Belanger MC, et al. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999; 54 (1-2): 39-48. (Pubitemid 29287671)
20. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002; 5 (2): 115-120. (Pubitemid 34662973)
21. Fava M, Rosenbaum JF, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000; 59 (2): 119-126. (Pubitemid 30317428)
22. Gagiano CA,. A double blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res 1993; 4: 145-152. (Pubitemid 24092522)
23. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic antidepressant study group. Int Clin Psychopharmacol 1999; 14 (6): 329-337. (Pubitemid 29531381)
24. Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001; 25 (1): 131-138. (Pubitemid 32493829)
25. Sir A, D'Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine xr in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66 (10): 1312-1320. (Pubitemid 41546512)
26. Boulenger JP, Hermes A, Huusom AK, Weiller E,. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. Curr Med Res Opin 2010; 26 (3): 605-614.
27. Silverstone PH, Ravindran A,. Once-daily venlafaxine extended release (xr) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine xr 360 study group. J Clin Psychiatry 1999; 60 (1): 22-28. (Pubitemid 29069881)
28. Beasley CM, Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991; 52 (7): 294-299.
29. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14 (2): 99-106. (Pubitemid 24120707)
30. Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 2002; 22 (2): 137-147. (Pubitemid 34289388)
31. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ,. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19 (2): 137-146. (Pubitemid 40321765)
32. Gillin JC, Rapaport M, Erman MK, et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 1997; 58 (5): 185-192. (Pubitemid 27242004)
33. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14 (6): 457-470. (Pubitemid 39626894)
34. Goldstein DJ, Lu Y, Detke MJ, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004; 45 (1): 17-28. (Pubitemid 38082504)
35. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006; 21 (6): 367-378.
36. Eli Lilly and Company. Duloxetine versus placebo and paroxetine in the acute treatment of major depression, study group a, ct registry id#4091, 2004, Eli Lilly and Company.24.
37. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002; 5 (2): 115-120. (Pubitemid 34662973)
38. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005; 39 (1): 43-53. (Pubitemid 39422285)
39. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63 (4): 308-315. (Pubitemid 34456358)
40. Flament MF, Lane RM, Zhu R, Ying Z,. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 1999; 14 (5): 259-275.
41. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine investigator study group. J Clin Psychopharmacol 1998; 18 (1): 19-25. (Pubitemid 28045630)
42. Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001; 25 (1): 131-138. (Pubitemid 32493829)
43. Gillin JC, Rapaport M, Erman MK, et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 1997; 58 (5): 185-192. (Pubitemid 27242004)
44. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24 (4): 389-399. (Pubitemid 38944137)
45. Hansen RA, Moore CG, Dusetzina SB, et al. Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Med Decis Making 2009; 29 (1): 91-103.
46. Kim HM, Zivin K, Ganoczy D, et al. Predictors of alternative antidepressant agent initiation among u. S. Veterans diagnosed with depression. Pharmacoepidemiol Drug Saf 2010; 19 (10): 1049-1056.
47. Garrison GD, Levin GM,. Factors affecting prescribing of the newer antidepressants. Annals Pharmacother 2000; 34 (1): 10-14. (Pubitemid 30058917)
48. Krebs EE, Gaynes BN, Gartlehner G, et al. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. Psychosomatics 2008; 49 (3): 191-198. (Pubitemid 351668719)
49. Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions. In: Methods guide for effectiveness and comparative effectiveness reviews. Rockville, MD: Agency for Healthcare Research and Quality. 2008. 1-15.
50. Gaynes BN, Farley JF, Dusetzina SB, et al. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? Depress Anxiety 2011; 28 (11): 989-998.